0001179110-21-001118.txt : 20210202
0001179110-21-001118.hdr.sgml : 20210202
20210202193556
ACCESSION NUMBER: 0001179110-21-001118
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210104
FILED AS OF DATE: 20210202
DATE AS OF CHANGE: 20210202
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KANGO SUJAY
CENTRAL INDEX KEY: 0001336503
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36065
FILM NUMBER: 21583557
MAIL ADDRESS:
STREET 1: 1028 CHAMBERS COURT
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACCELERON PHARMA INC
CENTRAL INDEX KEY: 0001280600
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 128 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-649-9200
MAIL ADDRESS:
STREET 1: 128 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4/A
1
edgar.xml
FORM 4/A -
X0306
4/A
2021-01-04
2021-01-06
0
0001280600
ACCELERON PHARMA INC
XLRN
0001336503
KANGO SUJAY
128 SIDNEY STREET
CAMBRIDGE
MA
02139
0
1
0
0
EVP, Chief Commercial Officer
Common Stock
2021-01-04
4
M
0
10000
40.61
A
13987
D
Option to Purchase Common Stock
40.61
2021-01-04
4
M
0
10000
0
D
2028-03-01
Common Stock
10000
40000
D
This Form 4 amendment is being filed to report the exercise of an option to purchase common stock that was inadvertently omitted from the original Form 4 filed on January 6, 2021.
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Reflects the holdings of the reporting person as of the date of the original Form 4 filed on January 6, 2021, taking into account the transactions set forth in such original Form 4 and the transaction set forth in this amendment.
The shares of common stock underlying this stock option award vested as to 25% of the shares on the first anniversary of February 12, 2018 and the remaining shares vest in equal quarterly installments over the following three years thereafter.
/s/ Adam M. Veness, as attorney-in-fact for Sujay Kango
2021-02-02